Sangamo: Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has shown the ability in preclinical studies to cross the blood-brain barrier.